Lisinopril全球市场规模、份额、趋势和成长分析报告（2026-2034）

预计Lisinopril市场将从 2025 年的 23.1 亿美元成长到 2034 年的 36 亿美元，2026 年至 2034 年的复合年增长率为 5.04%。

随着心血管疾病和高血压盛行率的不断上升，全球Lisinopril市场正稳步成长。Lisinopril是血管收缩素转化酵素（ACE）抑制剂，广泛用于治疗高血压、心臟衰竭和某些肾臟疾病。人们对心血管健康的日益重视以及基本药物可近性的提高，都极大地推动了这个市场的成长。

推动这一市场发展的主要因素是全球高血压负担日益加重，高血压是最常见的慢性疾病之一。久坐不动的生活方式、不健康的饮食习惯以及不断上升的压力水平都会导致心血管疾病的发病率增加。因此，医疗保健机构继续依赖像Lisinopril这样有效且价格合理的药物来控制血压并降低相关的健康风险。

未来几年，在人口老化和发展中地区医疗基础设施不断完善的推动下，Lisinopril市场预计将保持稳定成长。非专利处方药的普及以及各国政府旨在改善基本药物可近性的医疗政策将进一步促进市场扩张。持续关注心血管疾病预防预计将使全球对Lisinopril的需求保持强劲。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章：全球Lisinopril市场：以剂型划分

• 市场分析、洞察与预测
• 药片
• 液体

第五章：全球Lisinopril市场：依剂量强度划分

• 市场分析、洞察与预测
• 10 mg
• 20 mg
• 25 mg

第六章：全球Lisinopril市场：依病患年龄组别划分

• 市场分析、洞察与预测
• 孩子
• 成人

第七章 全球Lisinopril市场：依应用划分

• 市场分析、洞察与预测
• 高血压
• 心臟衰竭
• 心臟病发作
• 糖尿病肾臟病
• 其他用途

第八章：全球Lisinopril市场：依通路划分

• 市场分析、洞察与预测
• 医院药房
• 零售药房
• 网路药房

第九章：全球Lisinopril市场：依地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第十章 竞争格局

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第十一章：公司简介

• 主要公司的市占率分析
• 公司简介
  • AbbVie Inc
  • Amneal Pharmaceutical Inc
  • AstraZeneca
  • Apotex Inc
  • Aurobindo Pharma Ltd
  • Bausch Health Companies Inc
  • Cipla Limited
  • Hikma Pharmaceutical PLC
  • Lupin Limited
  • Merck & Co. Inc
  • Pfizer Inc
  • Sun Pharmaceutical Industries Limited

The Lisinopril Market size is expected to reach USD 3.60 Billion in 2034 from USD 2.31 Billion (2025) growing at a CAGR of 5.04% during 2026-2034.

The Global Lisinopril Market is growing steadily due to the rising prevalence of cardiovascular diseases and hypertension worldwide. Lisinopril, an angiotensin-converting enzyme (ACE) inhibitor, is widely prescribed to manage high blood pressure, heart failure, and certain kidney conditions. Increasing awareness about cardiovascular health and improved access to essential medications have significantly supported the expansion of this market.

The market is primarily driven by the growing global burden of hypertension, which is one of the most common chronic health conditions. Sedentary lifestyles, unhealthy dietary habits, and increasing stress levels have contributed to higher rates of cardiovascular disorders. As a result, healthcare providers continue to rely on effective and affordable medications like lisinopril to manage blood pressure and reduce related health risks.

In the coming years, the lisinopril market is expected to maintain steady growth due to the increasing aging population and expanding healthcare infrastructure in developing regions. Generic drug availability and government healthcare initiatives aimed at improving access to essential medicines will further support market expansion. With the ongoing focus on cardiovascular disease prevention, demand for lisinopril is expected to remain strong globally.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Dosage

• Tablet
• Liquid

By Dosage Strength

• 10 Mg
• 20 Mg
• 25 Mg

By Patient Age Group

• Children
• Adults

By Application

• Hypertension
• Heart Failure
• Heart Attack
• Diabetic Kidney Disease
• Other Applications

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

COMPANIES PROFILED

• AbbVie Inc, Amneal Pharmaceutical Inc, AstraZeneca, Apotex Inc, Aurobindo Pharma Ltd, Bausch Health Companies Inc, Cipla Limited, Hikma Pharmaceutical PLC, Lupin Limited, Merck Co Inc, Pfizer Inc, Sun Pharmaceutical Industries Limited
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL LISINOPRIL MARKET: BY DOSAGE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Dosage
• 4.2. Tablet Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Liquid Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL LISINOPRIL MARKET: BY DOSAGE STRENGTH 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Dosage Strength
• 5.2. 10 Mg Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. 20 Mg Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. 25 Mg Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL LISINOPRIL MARKET: BY PATIENT AGE GROUP 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Patient Age Group
• 6.2. Children Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Adults Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL LISINOPRIL MARKET: BY APPLICATION 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Application
• 7.2. Hypertension Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Heart Failure Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Heart Attack Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.5. Diabetic Kidney Disease Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.6. Other Applications Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL LISINOPRIL MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 8.1. Market Analysis, Insights and Forecast Distribution Channel
• 8.2. Hospital Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.3. Retail Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.4. Online Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL LISINOPRIL MARKET: BY REGION 2022-2034(USD MN)

• 9.1. Regional Outlook
• 9.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.2.1 By Dosage
  • 9.2.2 By Dosage Strength
  • 9.2.3 By Patient Age Group
  • 9.2.4 By Application
  • 9.2.5 By Distribution Channel
  • 9.2.6 United States
  • 9.2.7 Canada
  • 9.2.8 Mexico
• 9.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.3.1 By Dosage
  • 9.3.2 By Dosage Strength
  • 9.3.3 By Patient Age Group
  • 9.3.4 By Application
  • 9.3.5 By Distribution Channel
  • 9.3.6 United Kingdom
  • 9.3.7 France
  • 9.3.8 Germany
  • 9.3.9 Italy
  • 9.3.10 Russia
  • 9.3.11 Rest Of Europe
• 9.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.4.1 By Dosage
  • 9.4.2 By Dosage Strength
  • 9.4.3 By Patient Age Group
  • 9.4.4 By Application
  • 9.4.5 By Distribution Channel
  • 9.4.6 India
  • 9.4.7 Japan
  • 9.4.8 South Korea
  • 9.4.9 Australia
  • 9.4.10 South East Asia
  • 9.4.11 Rest Of Asia Pacific
• 9.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.5.1 By Dosage
  • 9.5.2 By Dosage Strength
  • 9.5.3 By Patient Age Group
  • 9.5.4 By Application
  • 9.5.5 By Distribution Channel
  • 9.5.6 Brazil
  • 9.5.7 Argentina
  • 9.5.8 Peru
  • 9.5.9 Chile
  • 9.5.10 South East Asia
  • 9.5.11 Rest of Latin America
• 9.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.6.1 By Dosage
  • 9.6.2 By Dosage Strength
  • 9.6.3 By Patient Age Group
  • 9.6.4 By Application
  • 9.6.5 By Distribution Channel
  • 9.6.6 Saudi Arabia
  • 9.6.7 UAE
  • 9.6.8 Israel
  • 9.6.9 South Africa
  • 9.6.10 Rest of the Middle East And Africa

Chapter 10. COMPETITIVE LANDSCAPE

• 10.1. Recent Developments
• 10.2. Company Categorization
• 10.3. Supply Chain & Channel Partners (based on availability)
• 10.4. Market Share & Positioning Analysis (based on availability)
• 10.5. Vendor Landscape (based on availability)
• 10.6. Strategy Mapping

Chapter 11. COMPANY PROFILES OF GLOBAL LISINOPRIL INDUSTRY

• 11.1. Top Companies Market Share Analysis
• 11.2. Company Profiles
  • 11.2.1 AbbVie Inc
  • 11.2.2 Amneal Pharmaceutical Inc
  • 11.2.3 AstraZeneca
  • 11.2.4 Apotex Inc
  • 11.2.5 Aurobindo Pharma Ltd
  • 11.2.6 Bausch Health Companies Inc
  • 11.2.7 Cipla Limited
  • 11.2.8 Hikma Pharmaceutical PLC
  • 11.2.9 Lupin Limited
  • 11.2.10 Merck & Co. Inc
  • 11.2.11 Pfizer Inc
  • 11.2.12 Sun Pharmaceutical Industries Limited